Title:
【発明の名称】ペミロラストカリウムの徐放性製剤
Document Type and Number:
Japanese Patent JP3116970
Kind Code:
B2
Abstract:
PURPOSE:To provide an extremely excellent sustained release preparation of pemirolast potassium known as an antiallergic agent, capable of keeping the effective blood concentration over a long period, having high storage stability and resistant to decomposition and the change in sustained releasability even after a long-term storage. CONSTITUTION:The objective sustained release preparation of pemirolast potassium (TBX) having the above effects and applicable by peroral administration or oral cavity application contains, as essential components, (A) TBX and (B) a hydroxypropyl methylcellulose preferably having a methoxyl group substitution degree of 1.9, 1.8 or 1.4 (especially 1.8) and a hydroxy-propoxyl group substitution degree of 0.25, 0.15 or 0.20 (especially 0.25) and having a viscosity of 40-11,200cp (especially 3,000-6,000cp) as 2% aqueous solution or a carboxymethylcellulose sodium salt preferably having an ether substitution degree of 0.5-0.94, a polymerization degree of 212-1,300 and a viscosity of 15-5,410cp as 1% aqueous solution. The amounts of the components A and B are 2-30wt.% and 10-90wt.% based on the total weight of the preparation, respectively.
More Like This:
| WO/2003/017999 | TREATMENT OF SCLERODERMA |
| JP2547125 | 2',3'-DIDEOXY-2',3'-DISUBSTITUTED NUCLEOTIDES AND THEIR PRODUCTION |
| WO/1984/000685 | PYRIDONE COMPOUNDS |
Inventors:
Takashi Yazaki
Kazunori Taguma
Manami Oguchi
Kazunori Taguma
Manami Oguchi
Application Number:
JP23674191A
Publication Date:
December 11, 2000
Filing Date:
June 12, 1991
Export Citation:
Assignee:
Mitsubishi Tokyo Pharmaceutical Co., Ltd.
International Classes:
A61K31/505; A61K31/519; A61K47/38; A61P11/02; A61P11/06; A61P27/16; A61P37/08; C07D471/04; A61K9/22; (IPC1-7): A61K31/519; A61K9/22; A61K47/38
Attorney, Agent or Firm:
Direct to Matsuyama